---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-23-000011"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2023-05-24T23:59:59+00:00"
generated_at: "2026-06-14T16:04:46.504016+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbCellera enters $701M co-investment with Canadian, BC governments for antibody drug development

## Summary
- CA$701M co-investment: AbCellera invests CA$401M, Canada CA$225M, BC CA$75M over 8 years.
- Builds capabilities to develop antibody drugs from target identification through Phase 1 clinical trials.
- Initial focus on cancer and immune diseases; plans to initiate up to 17 new drug development programs.
- Expected to create hundreds of new high-skilled jobs in Canada across computer science, life sciences, and manufacturing.
- Government contributions include repayable and conditionally repayable portions starting in 2032-2033.

## SEC filing metadata
- accession: 0001703057-23-000011
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2023-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000011/0001703057-23-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000011/abcl-20230524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-23-000011
- JSON: https://secwatch.observer/filing/0001703057-23-000011.json
- Plain text: https://secwatch.observer/filing/0001703057-23-000011.txt

## Key facts
- Material Agreements
  AbCellera Biologics Inc. entered into Canada Contribution Agreement with Government of Canada valued at Up to $166.7 million (CA$225.0 million) including non-repayable, repayable, and conditionally repaya (effective 2023-05-24).
  - Action: entry
  - Counterparty: Government of Canada
  - Value: Up to $166.7 million (CA$225.0 million) including non-repayable, repayable, and conditionally repaya
  - Effective: 2023-05-24
  source text: Pursuant to the Canada Contribution Agreement, the Government of Canada has committed up to $166.7 million (CA$225.0 million), of which $41.6 million (CA$56.2 million) is not repayable, $58.4 million (CA$78.8 million) is repayable and $66.7 million (CA$90.0 million) is conditionally repayable.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000011/0001703057-23-000011-index.htm
- Material Agreements
  AbCellera Biologics Inc. entered into BC Contribution Agreement with Government of British Columbia valued at Up to $55.6 million (CA$75.0 million) including partial reimbursement and conditional portions. (effective 2023-05-24).
  - Action: entry
  - Counterparty: Government of British Columbia
  - Value: Up to $55.6 million (CA$75.0 million) including partial reimbursement and conditional portions.
  - Effective: 2023-05-24
  source text: Pursuant to the BC Contribution Agreement, the Government of British Columbia has committed up to $55.6 million (CA$75.0 million) which includes partial reimbursement of certain eligible expenditures up to $27.8 million (CA$37.5 million) towards eligible infrastructure investments paid over five years; and a $27.8 million (CA$37.5 million) conditional portion paid upon achievement of certain defined milestones, including upon the Company’s undertaking of certain clinical trial activities in British Columbia.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000011/0001703057-23-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.